ARS Pharmaceuticals, Inc. Common Stock
SPRYARS Pharmaceuticals, Inc. (SPRY) is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of acute care medical conditions. The company primarily specializes in rescue treatments for severe allergies, anaphylaxis, and other urgent medical needs, aiming to improve patient outcomes through its proprietary drug delivery systems.
Company News
ARS Pharmaceuticals reported $32.5 million in revenue for Q3 2025, primarily from neffy epinephrine nasal spray sales. The company continues to expand market presence through direct-to-consumer campaigns and has strong cash reserves of $288.2 million.
ARS Pharmaceuticals reported strong Q2 2025 revenue of $15.7 million, driven by its needle-free epinephrine nasal spray neffy. Prescription volumes grew 180%, and commercial coverage reached 93%, though high operating costs led to a net loss of $44.9 million.
ARS Pharmaceuticals (SPRY) has seen a significant price increase over the past 12 weeks, indicating a positive trend. The company's fundamentals, including a Zacks Rank #2 (Buy) and positive earnings estimate revisions, suggest the trend could be sustainable.
ARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Insiders say these are penny stocks to buy. Do you agree? The post Penny Stocks To Buy? 3 That Insiders Are Investing $100,000+ In Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
